SWISSQUOTE BANK EUROPE SA | Market Closed - Swiss Exchange 11:20:01 2024-05-23 EDT | ||
| 101.9 USD | +0.18% |
|
| 1 month | +2.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
Static data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Swissquote Bank |
| ABIKSQ | |
| ISIN | CH1305627346 |
| Date issued | 2024-04-02 |
| Strike | 764 $ |
| Maturity | 2025-04-02 (305 Days) |
| Parity | 0.76 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 101.9 $ |
|---|---|
| Lowest since issue | 99.09 $ |
| Spread | 8.2 $ |
| Spread % | 0.80% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- ABIKSQ Certificat
